Newton G E, Parker J D
Department of Medicine, Mount Sinai Hospital, University of Toronto, Ontario, Canada.
Circulation. 1996 Aug 1;94(3):353-8. doi: 10.1161/01.cir.94.3.353.
beta-Blockers may reduce cardiac sympathetic activity in patients with heart failure by antagonizing beta-adrenergic receptors that facilitate sympathetic outflow to the heart. To explore this possible effect of beta-blockade, we measured cardiac norepinephrine spillover responses in patients with heart failure after the acute administration of either propranolol, a nonselective beta-blocker, or metoprolol, a beta 1-selective agent.
Eighteen patients were studied. Repeated intravenous doses of propranolol (0.5 mg; nine patients; left ventricular ejection fraction, 14 +/- 2%) or metoprolol (1.0 mg; nine patients; left ventricular ejection fraction, 18 +/- 2%) were administered until one of the following end points was reached: a 15% decrease in heart rate, left ventricular +dP/dt, or mean arterial blood pressure or a 5 mm Hg increase in left ventricular end-diastolic pressure. Propranolol (mean dose, 2.0 mg) and metoprolol (mean dose, 3.6 mg) caused similar reductions in heart rate, +dP/dt, and coronary sinus plasma flow. Cardiac norepinephrine spillover was reduced after propranolol (277 +/- 55 to 262 +/- 53 pmol/min, P < .05) but was increased after metoprolol (233 +/- 57 to 296 +/- 82 pmol/min, P < .05). In a comparison of the two groups, the decrease in spillover after propranolol was significantly different than the increase seen after metoprolol (P < .01).
The administration of a beta 1-selective antagonist was associated with increased cardiac norepinephrine spillover. In contrast, the administration of a nonselective beta-blocker until similar hemodynamic end points were reached caused a reduction in norepinephrine spillover. This suggests that in patients with heart failure, nonselective beta-blockade may have favorable inhibitory effects on cardiac sympathetic activity.
β受体阻滞剂可通过拮抗促进交感神经向心脏传出的β肾上腺素能受体,降低心力衰竭患者的心脏交感神经活性。为探究β受体阻滞剂的这种可能作用,我们在急性给予非选择性β受体阻滞剂普萘洛尔或β1选择性药物美托洛尔后,测量了心力衰竭患者的心脏去甲肾上腺素溢出反应。
对18例患者进行了研究。重复静脉注射普萘洛尔(0.5mg;9例患者;左心室射血分数为14±2%)或美托洛尔(1.0mg;9例患者;左心室射血分数为18±2%),直至达到以下终点之一:心率、左心室+dP/dt或平均动脉血压下降15%,或左心室舒张末期压力升高5mmHg。普萘洛尔(平均剂量2.0mg)和美托洛尔(平均剂量3.6mg)引起的心率、+dP/dt和冠状窦血浆流量的降低相似。普萘洛尔后心脏去甲肾上腺素溢出减少(从277±55降至262±53pmol/min,P<.05),但美托洛尔后增加(从233±57升至296±82pmol/min,P<.05)。在两组比较中,普萘洛尔后溢出的减少与美托洛尔后观察到的增加有显著差异(P<.01)。
给予β1选择性拮抗剂与心脏去甲肾上腺素溢出增加有关。相比之下,给予非选择性β受体阻滞剂直至达到相似的血流动力学终点会导致去甲肾上腺素溢出减少。这表明在心力衰竭患者中,非选择性β受体阻滞可能对心脏交感神经活性有有利的抑制作用。